Research Type: Reports

  • Medicare Part B Premium Dynamics Explained

  • Comparing Factors that Influence Pharmaceutical Pricing and Access in the US and five other Countries

  • Biosimilars in Medicare Part D: pricing dynamics and considerations

  • Evaluating Industry’s Drug Pricing Claims

  • Production Plus Profit Pricing (P-quad) FAQ

  • Biosimilars: Market Changes do not equal policy success

  • Ethics of Clinical Trials to Evaluate Biosimilars

  • Bottom-Up Pricing Estimate for P-quad

  • Modeling P-quad

  • Remdesivir Less Expensive for “Government Programs”? Not So Fast.

    Remdesivir Less Expensive for “Government Programs”? Not So Fast.